SCHEMBL26388248

SCHEMBL26388248

COc1ccc(CC23C4C5C2C2C3C4C52NC(=O)OC(C)(C)C)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
CACNA1B Q00975 2/20 0.39
CHRM1 P11229 1/20 0.39
HTT P42858 1/20 0.38
F2RL1 P55085 1/20 0.38
ALDH1A1 P00352 3/20 0.37
LMNA P02545 1/20 0.37
MEN1 O00255 1/20 0.37
NPC1 O15118 1/20 0.37
EPHX2 P34913 1/20 0.37
RAB9A P51151 1/20 0.37
KMT2A Q03164 1/20 0.37
NR1H4 Q96RI1 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KDM1A O60341 1/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
SAE1 Q9UBE0 1/20 0.36
UBA2 Q9UBT2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24622532 0.84 EPHX2 (0.36) PPARGPPARAALDH1A1NPC1EPHX2
SCHEMBL26387945 0.77 PPARG (0.42) PPARGPPARACACNA1BHTTF2RL1
SCHEMBL26388338 0.76 PPARG (0.42) PPARGPPARACACNA1BHTTF2RL1
SCHEMBL26388320 0.75 PPIA (0.43) PPARGPPARACACNA1BCHRM1HTT
SCHEMBL7256046 0.74 MEN1 (0.42) MEN1KMT2A
SCHEMBL18047975 0.74 CACNA1B (0.39) PPARGPPARACACNA1BALDH1A1LMNA
SCHEMBL25018543 0.73 TDP1 (0.38) MEN1KMT2A
SCHEMBL7652554 0.71 NPC1 (0.58) HTTALDH1A1LMNAMEN1NPC1
SCHEMBL8355292 0.69 CA12 (0.41) PPARGPPARACACNA1BHTTALDH1A1
SCHEMBL2493016 0.69 NPC1 (0.49) PPARGPPARACACNA1BHTTF2RL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT INC (US) 2023-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF CD47, CLTA, FCGR2A PPARG 1793/4885PPARA 914/4885CACNA1B 3900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.